Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2016

View Archived Issues

Galapagos updates on progress of cystic fibrosis candidates

Neurotrophic factor-secreting autologous MSCs show promising clinical results in ALS

Acetazolamide counters effects of Klotho hypomorphism on aging

Lilly files NDA for baricitinib for the oral treatment of rheumatoid arthritis

Adimab and iTeos to develop therapeutic antibodies for cancer

Berkeley Lights ships OptoSelect antibody discovery instrument to Amgen

FDA awards fast track designation to ZX-008 for Dravet syndrome

CEVEC and Beckman Research Institute sign collaboration agreement for CAPGT technology

First patient dosed in phase I trial evaluating TP-271

DNAzymes can be used for molecular probes to detect specific bacterial strains

EMA grants orphan drug designation to ARC-AAT

Sunshine Lake Pharma reports anti-HCV NS5B inhibitors

Hybrid Medical's gel H-100 evaluated in patients with Peyronie's disease

Trevena launches phase III clinical program for oliceridine

Pierre Fabre develops antitumor OSW-1 derivatives

Oncaspar receives marketing authorization in the E.U. as combination therapy for ALL

Roche presents ENT1 inhibitors

Profectus BioSciences initiates phase I testing of a vectored Ebola virus vaccine

Takeda develops FFAR2 agonists

Mologen and MD Anderson collaborate in trial of lefitolimod + ipilimumab

Aclaris Therapeutics starts phase III trials for A-101 in seborrheic keratosis

Gilead presents PI3Kdelta inhibitors

NIDA to conduct research on RespireRx compounds to treat drug abuse and addiction

Saniona and Upsher-Smith form neurological drug discovery and development collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...